A compound represented by Formula (1-I): ** Formula ** or a pharmaceutically acceptable salt thereof, in which: each of D and Z is independently absent or is an optionally substituted linear aliphatic group comprising from zero at eight carbons; each of A and E is independently absent or is a cyclic group; wherein each of said cyclic group is independently selected from the group consisting of aryl, heteroaryl, heterocyclic, C3-C8 cycloalkyl, and C3-C8 cycloalkenyl, each optionally substituted; T is absent or is an optionally substituted aliphatic group; In which one to four of A, D, E, T and Z is absent; Ring B is a five-membered heteroaryl, wherein said heteroaryl is optionally substituted; R1 in each case is independently selected from the group consisting of hydrogen, halogen, cyano, optionally substituted C1-C4 alkyl, -O-R11, -NRaRb, -C (O) R11, -CO2R 11 and -C (O) NRaRb; R11 in each case is independently hydrogen or optionally substituted C1-C8 alkyl; Ra and Rb in each case are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, and optionally substituted C2-C8 alkenyl; or Ra and Rb can be taken together with the nitrogen atom to which they are attached to form an optionally substituted heterocyclic or optionally substituted heteroaryl group; u is independently 1, 2 or 3; Q and J are: R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, and optionally substituted C3-C8 cycloalkyl; or alternatively, R3 and R4 can be taken together with the carbon atom to which they are attached to form optionally substituted C3-C8 cycloalkyl or optionally substituted heterocyclic; R5 in each case is independently hydrogen, optionally substituted C1-C8 alkyl, or optionally substituted C3-C8 cycloalkyl; R6 is selected from the group consisting of -C (O) -R12, -C (O) -C (O) -R12, -S (O) 2-R12 and -C (S) -R12; R12 in each case is i